Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Frontiers in Pharmacology|February 25, 2015
Corrigendum: The role of drug transporters in the kidney: lessons from tenofovirDarren M Moss
Frontiers in Pharmacology|November 27, 2014
The role of drug transporters in the kidney: lessons from tenofovirDarren M Moss, Megan Neary, Andrew Owen
Bioanalysis|September 10, 2016
Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matricesPaul Curley, Marco Siccardi, Darren M Moss, et al.
The Journal of Antimicrobial Chemotherapy|March 22, 2013
Predicting intestinal absorption of raltegravir using a population-based ADME simulationDarren M Moss, Marco Siccardi, David J Back, et al.
Frontiers in Pharmacology|April 28, 2015
Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporterDarren M Moss, Neill J Liptrott, Marco Siccardi, et al.
The Journal of Antimicrobial Chemotherapy|August 13, 2014
A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradicationDarren M Moss, Paul Curley, Alison Shone, et al.
Antimicrobial Agents and Chemotherapy|September 5, 2013
Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitroDarren M Moss, Neill J Liptrott, Paul Curley, et al.
Antimicrobial Agents and Chemotherapy|March 28, 2012
Divalent metals and pH alter raltegravir disposition in vitroDarren M Moss, Marco Siccardi, Matthew Murphy, et al.
Antimicrobial Agents and Chemotherapy|November 2, 2016
Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo InvestigationPaul Curley, Rajith K R Rajoli, Darren M Moss, et al.
Antimicrobial Agents and Chemotherapy|November 17, 2010
Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovirDarren M Moss, Wai San Kwan, Neill J Liptrott, et al.
Pageof 2